A randomised controlled trial of antivenom for red-bellied black snake envenoming
- Conditions
- Red-bellied black snake envenomingInjuries and Accidents - Other injuries and accidents
- Registration Number
- ACTRN12611000588998
- Lead Sponsor
- Geoff Isbister
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
1. Definite bite by a red-bellied black snake:
a.Expert identification of the snake or snake brought in and identified by a photograph sent to the investigators; OR
b.Characteristic description of a RBBS (black snake with red sides and cream/yellow ventral surface) AND detection of black snake (or black snake/tiger snake) on a snake venom detection kit.
2. Early evidence of envenoming (any of):
a. Non-specific systemic effects including two of nausea/vomiting, headache, abdominal pain, diarrhoea
b. Anticoagulant coagulopathy defined as an activated partial thromboplastin time above the normal range for the local laboratory
c. Significant local tissue injury with swelling, bruising and erythema >5 cm diameter
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with myotoxicity defined as a peak creatine kinase greater than 1000U/L. Creatine kinase is a standard biochemistry assay that will be done by the treating hospital (as part of standard care).[24 hours or the time after the first creatine kinase greater than 1000U/L]
- Secondary Outcome Measures
Name Time Method